Factors underlying sensitivity of cancers to small-molecule kinase inhibitors (original) (raw)

• Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nature Rev. Cancer 9, 28–39 (2009). This is a review summarizing the challenges and successes associated with the development of small-molecule kinase inhibitors to treat human cancer.
  Google Scholar
• Pegram, M. D. et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized antip185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659–2671 (1998).
  CAS PubMed Google Scholar
• Saltz, L. B. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201–1208 (2004).
  CAS PubMed Google Scholar
• Robert, F. et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19, 3234–3243 (2001).
  CAS PubMed Google Scholar
• Yan, L., Hsu, K. & Beckman, R. A. Antibody-based therapy for solid tumors. Cancer J. 14, 178–183 (2008).
  CAS PubMed Google Scholar
• Bibeau, F. et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27, 1122–1129 (2009). This paper reports a significant recent clinical finding that demonstrates the importance of activating KRAS mutations in the identification of colorectal cancer patients unlikely to respond to a kinase-targeted therapy.
  CAS PubMed Google Scholar
• Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnol. 26, 127–132 (2008).
  CAS Google Scholar
• Sharma, S. V. & Settleman, J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214–3231 (2007).
  CAS PubMed Google Scholar
• Shah, N. P. et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14, 485–493 (2008).
  CAS PubMed Google Scholar
• Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
  CAS PubMed Google Scholar
• Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472–480 (2002). This is a landmark report demonstrating the activity of a small-molecule kinase inhibitor in a solid tumour setting.
  CAS PubMed Google Scholar
• Sequist, L. V. First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients. J. Thorac. Oncol. 3, S143–145 (2008).
  PubMed Google Scholar
• Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmallcell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
  CAS PubMed Google Scholar
• Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
  CAS PubMed Google Scholar
• Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
  PubMed PubMed Central Google Scholar
• Verstovsek, S. et al. A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF). J. Clin. Oncol. 26 (abstr 7004) (2008).
  Google Scholar
• Futreal, P. A. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177–183 (2004).
  CAS Google Scholar
• McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936–19941 (2007).
  CAS PubMed PubMed Central Google Scholar
• Hipp, S. et al. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 90, 1433–1434 (2005).
  CAS PubMed Google Scholar
• Costa, L. J., Gemmill, R. M. & Drabkin, H. A. Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. Urology 69, 596–602 (2007).
  PubMed Google Scholar
• Younes, A. Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers. Autophagy 4, 707–709 (2008).
  CAS PubMed Google Scholar
• Le Tourneau, C., Faivre, S., Serova, M. & Raymond, E. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br. J. Cancer 99, 1197–1203 (2008).
  CAS PubMed PubMed Central Google Scholar
• Weinstein, I. B. Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science 297, 63–64 (2002).
  CAS PubMed Google Scholar
• Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163–1167 (2004).
  Article CAS PubMed Google Scholar
• Smolen, G. A. et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA665752. Proc. Natl Acad. Sci. USA 103, 2316–2321 (2006).
  CAS PubMed PubMed Central Google Scholar
• Lutterbach, B. et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 67, 2081–2088 (2007).
  CAS PubMed Google Scholar
• Knudsen, B. S. & Vande Woude, G. Showering cMETdependent cancers with drugs. Curr. Opin. Genet. Dev. 18, 87–96 (2008).
  CAS PubMed Google Scholar
• Kunii, K. et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 68, 2340–2348 (2008).
  CAS PubMed Google Scholar
• Dutt, A. et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl Acad. Sci. USA 105, 8713–8717 (2008).
  CAS PubMed PubMed Central Google Scholar
• George, R. E. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975–978 (2008).
  CAS PubMed PubMed Central Google Scholar
• McDermott, U. et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 68, 3389–3395 (2008).
  CAS PubMed Google Scholar
• Koivunen, J. P. et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14, 4275–4283 (2008).
  CAS PubMed PubMed Central Google Scholar
• Morris, S. W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281–1284 (1994).
  CAS PubMed Google Scholar
• Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967–970 (2008).
  CAS PubMed Google Scholar
• Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in nonsmallcell lung cancer. Nature 448, 561–566 (2007).
  CAS PubMed Google Scholar
• Chen, Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971–974 (2008).
  CAS PubMed Google Scholar
• Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002). This paper describes an important finding of cancer genome resequencing efforts by identifying BRAF mutations as very frequent in some human cancers.
  CAS PubMed Google Scholar
• Montagut, C. & Settleman, J. Targeting the RAFMEKERK pathway in cancer therapy. Cancer Lett. 11 February 2009 (doi:10.1016/j.canlet.2009.01.022).
  CAS PubMed Google Scholar
• Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3kinases as regulators of growth and metabolism. Nature Rev. Genet. 7, 606–619 (2006).
  CAS PubMed Google Scholar
• Ihle, N. T. et al. Mutations in the phosphatidylinositol3kinase pathway predict for antitumor activity of the inhibitor PX866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 69, 143–150 (2009).
  CAS PubMed PubMed Central Google Scholar
• Sharma, S. V., Fischbach, M. A., Haber, D. A. & Settleman, J. “Oncogenic shock”: explaining oncogene addiction through differential signal attenuation. Clin. Cancer Res. 12, 4392s–4395s (2006).
  CAS PubMed Google Scholar
• Sharma, S. V. et al. A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10, 425–435 (2006).
  CAS PubMed PubMed Central Google Scholar
• Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006). This is a highly cited report demonstrating the importance of a specific activating kinase allele ( BRAF ) as a drug-sensitizing mutation based on cell culture findings.
  CAS PubMed Google Scholar
• Pratilas, C. A. et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 68, 9375–9383 (2008).
  CAS PubMed PubMed Central Google Scholar
• Kang, S. et al. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12, 201–214 (2007).
  CAS PubMed PubMed Central Google Scholar
• Prieur, A., Tirode, F., Cohen, P. & Delattre, O. EWS/FLI1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell Biol. 24, 7275–7283 (2004).
  CAS PubMed PubMed Central Google Scholar
• Scotlandi, K. et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res. 56, 4570–4574 (1996).
  CAS PubMed Google Scholar
• Scotlandi, K. et al. Antitumor activity of the insulin-like growth factorI receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 65, 3868–3876 (2005).
  CAS PubMed Google Scholar
• Tolcher, A. W., Rothenberg, M. L. & Rodon, J. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J. Clin. Oncol. 25 (18 suppl), 3002 (2007).
  Google Scholar
• Wu, Z., Gioeli, D., Conaway, M., Weber, M. J. & Theodorescu, D. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate 68, 935–944 (2008).
  CAS PubMed PubMed Central Google Scholar
• Noro, R. et al. PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Int. J. Oncol. 31, 1157–1163 (2007).
  CAS PubMed Google Scholar
• Berns, K. et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395–402 (2007).
  CAS PubMed Google Scholar
• Lin, W. M. et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 68, 664–673 (2008).
  CAS PubMed Google Scholar
• Singer, C. F., Kostler, W. J. & Hudelist, G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim. Biophys. Acta 1786, 105–113 (2008).
  CAS PubMed Google Scholar
• Nagata, Y. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117–127 (2004).
  CAS PubMed Google Scholar
• Mellinghoff, I. K. et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012–2024 (2005). This is a clinical report demonstrating the activity of an EGFR-targeted therapy in a genotype-defined sub-population of treated glioma pateints.
  CAS PubMed Google Scholar
• Endoh, H., Yatabe, Y., Kosaka, T., Kuwano, H. & Mitsudomi, T. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J. Thorac. Oncol. 1, 629–634 (2006).
  PubMed Google Scholar
• Eichhorn, P. J. et al. Phosphatidylinositol 3kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3kinase inhibitor NVP-BEZ235. Cancer Res. 68, 9221–9230 (2008).
  CAS PubMed PubMed Central Google Scholar
• Engelman, J. A. et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 116, 2695–2706 (2006).
  CAS PubMed PubMed Central Google Scholar
• Parsons, R. Human cancer, PTEN and the PI3 kinase pathway. Semin. Cell Dev. Biol. 15, 171–176 (2004).
  CAS PubMed Google Scholar
• Li, J., Zhao, M., He, P., Hidalgo, M. & Baker, S. D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer Res. 13, 3731–3737 (2007).
  CAS PubMed Google Scholar
• Rudin, C. M. et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J. Clin. Oncol. 26, 1119–1127 (2008).
  CAS PubMed Google Scholar
• Hamilton, M. et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin. Cancer Res. 12, 2166–2171 (2006).
  CAS PubMed Google Scholar
• Hughes, A. N. et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J. Clin. Oncol. 27, 1220–1226 (2009).
  CAS PubMed PubMed Central Google Scholar
• Li, J. et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol. Ther. 6, 432–438 (2007).
  CAS PubMed Google Scholar
• Cusatis, G. et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl Cancer Inst. 98, 1739–1742 (2006).
  CAS PubMed Google Scholar
• Delbaldo, C. et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin. Cancer Res. 12, 6073–6078 (2006).
  CAS PubMed Google Scholar
• Petain, A. et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin. Cancer Res. 14, 7102–7109 (2008).
  CAS PubMed Google Scholar
• Amador, M. L. et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 64, 9139–9143 (2004).
  CAS PubMed Google Scholar
• Huang, C. L. et al. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer 64, 346–351 (2009).
  PubMed Google Scholar
• Liu, W. et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin. Cancer Res. 9, 1009–1012 (2003).
  CAS PubMed Google Scholar
• Shepherd, F. A. et al. Erlotinib in previously treated nonsmallcell lung cancer. N. Engl. J. Med. 353, 123–132 (2005).
  CAS PubMed Google Scholar
• Thatcher, N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmallcell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527–1537 (2005).
  CAS PubMed Google Scholar
• Tiseo, M. et al. Epidermal growth factor receptor intron1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. J. Thorac. Oncol. 3, 1104–1111 (2008).
  PubMed Google Scholar
• Liu, G. et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in nonsmallcell lung cancer patients treated with gefitinib. Pharmacogenomics J. 8, 129–138 (2008).
  CAS PubMed Google Scholar
• Fitzgerald, L. M. et al. Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer Prostatic Dis. (2008).
• Morimoto, Y. et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98, 2245–2250 (2003).
  CAS PubMed Google Scholar
• Sasaki, H. et al. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer. Oncol. Rep. 20, 1125–1130 (2008).
  CAS PubMed Google Scholar
• Thussbas, C. et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J. Clin. Oncol. 24, 3747–3755 (2006).
  CAS PubMed Google Scholar
• Kilpivaara, O. et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nature Genet. 41, 455–459 (2009). This paper presents a clinical finding implicating a germline kinase gene polymorphism in cancer predisposition.
  CAS PubMed Google Scholar
• Dressman, M. A. et al. Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571). Clin. Cancer Res. 10, 2265–2271 (2004).
  CAS PubMed Google Scholar
• Hirata, A. et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 62, 2554–2560 (2002).
  CAS PubMed Google Scholar
• Amin, D. N., Hida, K., Bielenberg, D. R. & Klagsbrun, M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res. 66, 2173–2180 (2006).
  CAS PubMed Google Scholar
• Amin, D. N., Bielenberg, D. R., Lifshits, E., Heymach, J. V. & Klagsbrun, M. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR2 dependence in tumor endothelial cells. Microvasc. Res. 76, 15–22 (2008).
  CAS PubMed Google Scholar
• Yano, S. et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68, 9479–9487 (2008). This is a report describing the role of an RTK ligand (HGF) in conferring resistance to therapy with an EGFR-targeted kinase inhibitor.
  CAS PubMed Google Scholar
• Gurevich, F. & Perazella, M. A. Renal effects of anti-angiogenesis therapy: update for the internist. Am. J. Med. 122, 322–328 (2009).
  CAS PubMed Google Scholar
• Engelman, J. A. & Settleman, J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 18, 73–79 (2008).
  CAS PubMed Google Scholar
• Kobayashi, S. et al. EGFR mutation and resistance of nonsmallcell lung cancer to gefitinib. N. Engl. J. Med. 352, 786–792 (2005). This is a report describing the detection of a secondary mutation in EGFR that confers acquired resistance to EGFR TKIs.
  CAS PubMed Google Scholar
• Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117–125 (2002).
  CAS PubMed Google Scholar
• Cools, J. et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 64, 6385–6389 (2004).
  CAS PubMed Google Scholar
• Blencke, S. et al. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol. 11, 691–701 (2004).
  CAS PubMed Google Scholar
• Yun, C. H. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA 105, 2070–2075 (2008).
  CAS PubMed PubMed Central Google Scholar
• Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007). This is a report describing amplification of the gene encoding the MET kinase in NSCLC patients with acquired resistance to EGFR TKI therapy.
  CAS PubMed Google Scholar
• Bean, J. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci. USA 104, 20932–20937 (2007).
  CAS PubMed PubMed Central Google Scholar
• Kobayashi, S. et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 65, 7096–7101 (2005).
  CAS PubMed Google Scholar
• Kwak, E. L. et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin. Cancer Res. 12, 4283–4287 (2006).
  CAS PubMed PubMed Central Google Scholar
• Li, D. et al. Bronchial and peripheral murine lung carcinomas induced by T790ML858R mutant EGFR respond to HKI272 and rapamycin combination therapy. Cancer Cell 12, 81–93 (2007).
  CAS PubMed Google Scholar
• Godin-Heymann, N. et al. The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol. Cancer Ther. 7, 874–879 (2008).
  CAS PubMed Google Scholar
• Sergina, N. V. et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437–441 (2007).
  CAS PubMed PubMed Central Google Scholar
• Guix, M. et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118, 2609–2619 (2008).
  CAS PubMed PubMed Central Google Scholar
• Bachleitner-Hofmann, T. et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol. Cancer Ther. 7, 3499–3508 (2008).
  CAS PubMed Google Scholar
• Sun, S. Y. et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65, 7052–7058 (2005).
  CAS PubMed Google Scholar
• O'Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500–1508 (2006).
  CAS PubMed PubMed Central Google Scholar
• Zhang, H. et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest. 117, 730–738 (2007).
  CAS PubMed PubMed Central Google Scholar
• Wang, X. et al. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res. 68, 7409–7418 (2008).
  CAS PubMed PubMed Central Google Scholar
• Fan, Q. W. et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341–349 (2006).
  CAS PubMed PubMed Central Google Scholar
• Ji, H. et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res. 67, 4933–4939 (2007).
  CAS PubMed Google Scholar
• Adjei, A. A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139–2146 (2008).
  CAS PubMed Google Scholar
• Lorusso, P. M. et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI1040 in patients with advanced malignancies. J. Clin. Oncol. 23, 5281–5293 (2005).
  CAS PubMed Google Scholar
• Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Med. 14, 1351–1356 (2008).
  CAS PubMed Google Scholar
• O'Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994–1004 (2003).
  CAS PubMed Google Scholar
• Inoue, A. et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced nonsmallcell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. 24, 3340–3346 (2006).
  CAS PubMed Google Scholar
• Sequist, L. V. et al. First-line gefitinib in patients with advanced nonsmallcell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 26, 2442–2449 (2008). This clinical study demonstrates the utility of pre-selecting NSCLC patients with EGFR mutations for treatment with EGFR TKIs.
  CAS PubMed Google Scholar
• Asahina, H. et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br. J. Cancer 95, 998–1004 (2006).
  CAS PubMed PubMed Central Google Scholar
• Tamura, K. et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br. J. Cancer 98, 907–914 (2008).
  CAS PubMed PubMed Central Google Scholar
• Heinrich, M. C. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342–4349 (2003).
  CAS PubMed Google Scholar
• Thomas, R. K. et al. High-throughput oncogene mutation profiling in human cancer. Nature Genet. 39, 347–351 (2007).
  CAS PubMed Google Scholar
• Tsai, J. et al. Discovery of a selective inhibitor of oncogenic BRaf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041–3046 (2008).
  CAS PubMed PubMed Central Google Scholar
• Tokarski, J. S. et al. The structure of Dasatinib (BMS354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66, 5790–5797 (2006).
  CAS PubMed Google Scholar
• Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399–401 (2004).
  CAS PubMed Google Scholar
• Tsang, C. K., Qi, H., Liu, L. F. & Zheng, X. F. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 12, 112–124 (2007).
  CAS PubMed Google Scholar
• Gomez, H. L. et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J. Clin. Oncol. 26, 2999–3005 (2008).
  CAS PubMed Google Scholar
• Hilberg, F. et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68, 4774–4782 (2008).
  CAS PubMed Google Scholar
• Gunby, R. H. et al. Sensitivity to imatinib but low frequency of the TEL/PDGFRβ fusion protein in chronic myelomonocytic leukemia. Haematologica 88, 408–415 (2003).
  CAS PubMed Google Scholar
• Magnusson, M. K., Meade, K. E., Nakamura, R., Barrett, J. & Dunbar, C. E. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood 100, 1088–1091 (2002).
  CAS PubMed Google Scholar
• Christensen, J. G. et al. Cytoreductive antitumor activity of PF2341066, a novel inhibitor of anaplastic lymphoma kinase and cMet, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6, 3314–3322 (2007).
  CAS PubMed Google Scholar
• Tuveson, D. A. et al. STI571 inactivation of the gastrointestinal stromal tumor cKIT oncoprotein: biological and clinical implications. Oncogene 20, 5054–5058 (2001).
  CAS PubMed Google Scholar
• Illmer, T. & Ehninger, G. FLT3 kinase inhibitors in the management of acute myeloid leukemia. Clin. Lymphoma Myeloma 8 (Suppl. 1), 24–34 (2007).
  Google Scholar
• Salgia, R. et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J. Clin. Oncol. 26, 15S (2008).
  Google Scholar
• Finn, R. S. et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res. Treat 105, 319–326 (2007).
  CAS PubMed Google Scholar
• Fizazi, K. The role of Src in prostate cancer. Ann. Oncol. 18, 1765–1773 (2007).
  CAS PubMed Google Scholar
• Ishizawar, R. & Parsons, S. J. cSrc and cooperating partners in human cancer. Cancer Cell 6, 209–214 (2004).
  CAS PubMed Google Scholar
• Smalley, K. S. & Flaherty, K. T. Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br. J. Cancer 100, 431–435 (2009).
  CAS PubMed PubMed Central Google Scholar
• Warner, S. L., Stephens, B. J. & Von Hoff, D. D. Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer. Curr. Oncol. Rep. 10, 122–129 (2008).
  CAS PubMed Google Scholar
• Pao, W. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306–13311 (2004).
  CAS PubMed PubMed Central Google Scholar
• Li, D. et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27, 4702–4711 (2008).
  CAS PubMed PubMed Central Google Scholar
• Song, L. et al. Dasatinib (BMS354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 66, 5542–5548 (2006).
  CAS PubMed Google Scholar
• Beadling, C. et al. KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 14, 6821–6828 (2008).
  CAS PubMed Google Scholar
• Hodi, F. S. et al. Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 26, 2046–2051 (2008). This clinical study demonstrates response to imatinib in rare melanomas harbouring activating mutations of the cKIT kinase.
  CAS PubMed Google Scholar
• Kim, J. W. et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 272, 296–306 (2008).
  CAS PubMed Google Scholar